Closed Loop Medicine appoints Paul Jakimciw as Chief Product Officer and Dr Myles Furnace as VP, Commercial Strategy, Partnerships and Market Access. The announcement comes following the company’s recent £13m financing which is being used to support its personalised drug + digital therapy combination products which are being developed to improve outcomes for patients and clinicians through precision dosing.
Paul Jakimciw joins Closed Loop Medicine bringing almost two decades of experience working with and inside fast growth businesses, including a strong focus on digital health with most recent experience at Ada Health and Push Doctor.
Dr Myles Furnace joins from Ipsen a global, mid-sized biopharmaceutical company where he focused on digital health and Real-World Evidence. Myles is an NHS trained physician.
At Closed Loop Medicine Paul will lead the combination product teams to build a product led organisation that can break innovative new ground while upholding the highest quality standards to deliver end value to patients, safely.
Paul has experience in fast growth technology, as partner and ultimately CEO of Albion, Paul was part to the team that helped scale Skype from beta page to half a billion users, Zoopla to IPO and helped Corporate’s like Telefonica to innovate by creating companies like Giffgaff.
Post Albion, Paul then focussed almost solely on the then emerging digital health sector. He was part of the Executive team who launched Push Doctor before joining Ada, a broad based diagnostic AI and SaMD, also as CPO. There the team successfully scaled a consumer application to over 14m users, alongside SaaS offers to Life Sciences and an enterprise solutions adopted by multiple health systems across Europe and the US.
Paul has developed deep expertise across the sector also serving the boards of Veta Health, Numan and The Cardinal Clinic.
Paul Jakimciw said ‘At CLM we have an opportunity to develop a completely new type of proposition spanning drug and digital to create an innovative therapeutic pathway not previously seen. We’ve already made significant breakthroughs in developing novel IP, validating new clinical hypothesis and building the core of a best in class team. The next 24 months will see us build on that to bring solutions to market that have the opportunity to positive impact millions of lives’
Dr Myles Furnace is a qualified physician having started his career within the NHS, working in emergency medicine and oncology before transitioning into the pharmaceutical industry. He has held multiple roles across Medical Affairs, Commercial and Digital functions, overseeing strategy, partnerships, leading key digital initiatives and driving innovation across the organisation. His most recent role, as Data Strategy and Real-World Evidence Director, saw him develop integrated evidence plans for key assets and identify RWE opportunities as part the broader medical transformation within the organisation. He has a true passion for digital health and encouraging the continued intersection of medicine and technology to deliver data driven solutions and improve outcomes for patients.
Myles joins the company to support commercialisation of its existing and pipeline products with pharma and specialty generics co-development partners.
Myles Said: “I’m thrilled to be joining Closed Loop Medicine at a time where healthcare and technology continue to propel forward. I look forward to working with this passionate team and supporting them to achieve their mission to improve outcomes for patients by creating personalised and integrated solutions.”
On the appointments Hakim Yadi, CEO of Closed Loop Medicine said: Paul and Myles’ are important appointments and mark a step change for the Company as we build our patient-centric product focused combination solutions in partnership with the life and health sciences sector.
About Closed Loop Medicine
Closed Loop Medicine (the “Company”) is the global leader in the development of single prescription drug plus digital therapy combination products developed to optimise dosing on an individual level to improve patient outcomes. The company was founded by an experienced team of healthcare professionals, entrepreneurs and life scientists with experience of both drug and software development, as well as extensive health system innovation experience. The company has two products in development for hypertension and insomnia. It has further products in its pipeline for a wide portfolio of chronic diseases. The Company ensures that both patient and clinician are at the centre of its products design and development.